Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTRON vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 12-15 hours in patients with normal renal function. In end-stage renal disease (ESRD), half-life may extend to 24-30 hours, requiring dose adjustment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hydrochlorothiazide: primarily excreted unchanged in urine. Pargyline: metabolized via MAO (its target) and other pathways; metabolites excreted renally.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion accounts for approximately 90% of elimination, with 70% as unchanged drug and 20% as metabolites. Biliary/fecal excretion accounts for the remaining 10%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 95% bound to albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.3 L/kg, indicating distribution primarily in extracellular fluid. Higher Vd in heart failure (0.5 L/kg) due to increased tissue perfusion.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 60-70% due to first-pass metabolism; significantly reduced by food (decrease by 30%).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
e GFR ≥30 m L/min/1.73 m²: No adjustment. e GFR <30 m L/min/1.73 m²: Contraindicated due to valsartan component.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Use caution; maximum amiodipine dose 5 mg daily. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not established for patients <18 years.
Not established; avoid use in children.
Initiate at lowest dose (5 mg/2.5 mg once daily) due to increased sensitivity and reduced hepatic/renal function.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
This drug is no longer approved by FDA. Historical black box warning: Pargyline may cause hypertensive crisis when used with certain foods (tyramine-rich) or drugs.
None
Hypertensive crisis due to dietary tyramine or sympathomimetic drugs,Orthostatic hypotension,Electrolyte imbalance from thiazide,Renal impairment,Hepatic encephalopathy
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Concurrent use of other MAOIs or selective serotonin reuptake inhibitors (SSRIs),Pheochromocytoma,Hypersensitivity to sulfonamides (cross-reactivity with thiazide),Anuria
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-tyramine foods (aged cheese, cured meats, fermented foods) due to potential hypertensive crisis with reserpine; avoid excessive sodium intake; maintain adequate potassium intake; limit alcohol.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restriction and oligohydramnios. Third trimester: Neonatal adverse effects including bone marrow suppression and pulmonary hypertension.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Excreted in breast milk; M/P ratio 0.05-0.2. Contraindicated due to risk of neonatal toxicity (myelosuppression, carcinogenesis).
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended as use is prohibited. If inadvertent exposure occurs, discontinue immediately.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
EUTRON (combination of hydrochlorothiazide and reserpine) is an older antihypertensive. Reserpine depletes catecholamines, requiring weeks for full effect; may cause depression and nasal congestion. Hydrochlorothiazide increases uric acid; monitor gout and hypokalemia. Discontinue 1-2 weeks before electroconvulsive therapy due to interaction with reserpine.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take as prescribed; do not stop suddenly as blood pressure may rise.,May cause dizziness or drowsiness; avoid driving if affected.,Report any mood changes, especially depression or suicidal thoughts.,Possible nasal congestion; use saline spray if needed.,Avoid alcohol as it may enhance side effects.,Use sunscreen; may increase sensitivity to sunlight.,May increase blood sugar; monitor if diabetic.,May cause dry mouth; use sugarless gum or candy.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTRON vs ALDORIL 25, answered by our medical review team.
EUTRON is a Antihypertensive that works by EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTRON and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTRON is: Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTRON and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTRON is classified as Category C. First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restricti. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.